PCN65 ESTIMATED COSTS OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) FOR RECURRENT OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE CHECKMATE 141 TRIAL IN SPAIN

Authors :: J. Suarez Rodriguez
M. Contente
James W. Shaw
C. Polanco Sánchez
M. Venkatachalam
Source :: Value in Health. 22:S448
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Health Policy
Internal medicine
Public Health, Environmental and Occupational Health
Checkmate
Medicine
Basal cell
business
Adverse effect
Head and neck

Tools